Cargando…

nab-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors

Tumors recognized by the host immune system are associated with better survival. However, the immune system is often suppressed in patients with established tumor burden. Stimulating the immune system to detect and kill tumor cells has been a challenge in cancer therapy for some time. Recently, nove...

Descripción completa

Detalles Bibliográficos
Autor principal: Soliman, Hatem H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5189972/
https://www.ncbi.nlm.nih.gov/pubmed/28053544
http://dx.doi.org/10.2147/OTT.S122974
_version_ 1782487325582819328
author Soliman, Hatem H
author_facet Soliman, Hatem H
author_sort Soliman, Hatem H
collection PubMed
description Tumors recognized by the host immune system are associated with better survival. However, the immune system is often suppressed in patients with established tumor burden. Stimulating the immune system to detect and kill tumor cells has been a challenge in cancer therapy for some time. Recently, novel cancer immunotherapies, such as immune checkpoint inhibitors, monoclonal antibodies, and vaccine therapies, have emerged as promising therapeutic approaches for many solid tumors. However, for some tumors, immunotherapy alone has not provided significant benefits, and some may even be fully resistant to immunotherapy. It has been suggested that the immune system may require “priming” before an immunotherapy can elicit an immune response. Although chemotherapies are believed to be immunosuppressive, when given at the right dose and sequence these agents may provide this “priming” effect for the immune system. In addition to direct cytotoxic killing of tumor cells, standard chemotherapeutic agents can elicit immunogenicity through various mechanisms. This review highlights the general immunomodulatory properties of chemotherapy agents. It also provides a rationale for combined therapy with nab-paclitaxel and immune checkpoint inhibitors. Recent clinical trial data with these combination regimens in solid tumors are presented, along with a summary of ongoing trials.
format Online
Article
Text
id pubmed-5189972
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-51899722017-01-04 nab-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors Soliman, Hatem H Onco Targets Ther Review Tumors recognized by the host immune system are associated with better survival. However, the immune system is often suppressed in patients with established tumor burden. Stimulating the immune system to detect and kill tumor cells has been a challenge in cancer therapy for some time. Recently, novel cancer immunotherapies, such as immune checkpoint inhibitors, monoclonal antibodies, and vaccine therapies, have emerged as promising therapeutic approaches for many solid tumors. However, for some tumors, immunotherapy alone has not provided significant benefits, and some may even be fully resistant to immunotherapy. It has been suggested that the immune system may require “priming” before an immunotherapy can elicit an immune response. Although chemotherapies are believed to be immunosuppressive, when given at the right dose and sequence these agents may provide this “priming” effect for the immune system. In addition to direct cytotoxic killing of tumor cells, standard chemotherapeutic agents can elicit immunogenicity through various mechanisms. This review highlights the general immunomodulatory properties of chemotherapy agents. It also provides a rationale for combined therapy with nab-paclitaxel and immune checkpoint inhibitors. Recent clinical trial data with these combination regimens in solid tumors are presented, along with a summary of ongoing trials. Dove Medical Press 2016-12-21 /pmc/articles/PMC5189972/ /pubmed/28053544 http://dx.doi.org/10.2147/OTT.S122974 Text en © 2017 Soliman. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Soliman, Hatem H
nab-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors
title nab-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors
title_full nab-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors
title_fullStr nab-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors
title_full_unstemmed nab-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors
title_short nab-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors
title_sort nab-paclitaxel as a potential partner with checkpoint inhibitors in solid tumors
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5189972/
https://www.ncbi.nlm.nih.gov/pubmed/28053544
http://dx.doi.org/10.2147/OTT.S122974
work_keys_str_mv AT solimanhatemh nabpaclitaxelasapotentialpartnerwithcheckpointinhibitorsinsolidtumors